Shares of medical device company Artivion (NYSEAORT)
fell 11.2% in the morning session after the company reported weak fourth-quarter 2024 results, as both revenue and EPS missed Wall Street's expectations. While revenue did grow 4% year-on-year, it still fell short, partly due to the late-November cybersecurity incident that disrupted operations.
Medical device company Artivion (NYSEAORT) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 3.9% year on year to $97.31 million. The company’s full-year revenue guidance of $427.5 million at the midpoint came in 0.6% below analysts’ estimates. Its non-GAAP loss of $0 per share was significantly below analysts’ consensus estimates.
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including Artivion (NYSEAORT) and its peers.
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including ICU Medical (NASDAQICUI) and its peers.
Looking back on medical devices & supplies - cardiology, neurology, vascular stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Penumbra (NYSEPEN) and its peers.
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including Merit Medical Systems (NASDAQMMSI) and its peers.
